Dodge & Cox Upped Its Eli Lilly & Co (NYSE:LLY) Position as Price Declined by $127.88 Million

May 17, 2018 - By Arnold Ferreira

Eli Lilly and Company (NYSE:LLY) Corporate LogoBig Money Sentiment increased to 1.1 in 2017 Q4. It has change of 0.21, from 2017Q3’s 0.89. The ratio increased due to LLY positioning: 42 sold and 380 reduced. 117 funds acquired stakes and 346 increased stakes. Investors holded 827.83 million in 2017Q3 but now own 827.08 million shares or 0.09% less. Guardian Co has invested 0.83% in Eli Lilly and Company (NYSE:LLY). 646,800 are owned by Point72 Asset Mngmt L P. Shell Asset Communication invested in 0.49% or 289,542 shs. Raymond James & Associate accumulated 392,591 shs. Schroder Mgmt Group owns 2.30 million shs or 0.32% of their US capital. 210,606 are owned by Hartford Inv Mngmt Com. Alphaone Inv Service Ltd Limited Liability Company accumulated 936 shs. Bp Public Limited Com invested in 0.34% or 113,000 shs. Princeton Strategies Lc holds 17,865 shs. Whittier Tru Of Nevada invested in 8,292 shs. Hsbc Holdg Public Ltd Limited Liability Company holds 0.26% in Eli Lilly and Company (NYSE:LLY) or 2.09M shs. River & Mercantile Asset Mgmt Ltd Liability Partnership accumulated 85,800 shs. Eads And Heald Inv Counsel accumulated 7,159 shs. Norinchukin National Bank The reported 128,415 shs stake. Oxbow Advsr Llc reported 5,436 shs.

LLY had 11 sales and 0 insider buys since December 11, 2017. This’s net activity of $48.49 million. 9,027 shs were sold by Simmons Jeffrey N, worth $708,620 on Tuesday, May 1. 22,544 shs were sold by Mahony Susan, worth $1.81 million. On Friday, March 16 $237,600 worth of Eli Lilly and Company (NYSE:LLY) was sold by Smiley Joshua L. 900 shs valued at $72,981 were sold by Zakrowski Donald A on Monday, February 5.

In Eli Lilly & Co (NYSE:LLY) was upped the holdings held by Dodge & Cox. The rise is 8.23% according to 2018Q1 SEC filling. Eli Lilly & Co (NYSE:LLY) declined 11.06% with the market as Dodge & Cox bought 1.66 million shares. Dodge & Cox is holding 21.84M shares, compared to 20.18 million last quarter. The reported value is $1.69 billion. $82.86 billion is the MC of Eli Lilly & Co. The stock decreased 0.57% or $0.47 during the last trading session, touching $81.18.Eli Lilly and Company has volume of 3.61M shares. Since May 17, 2017 LLY has declined 10.19% and is downtrending. LLY underperformed by 21.74% the S&P 500.

Dodge & Cox operates about $123.87 billion US longs. It decreased its stake in Maxim Integrated Products Inc (NASDAQ:MXIM) by 916,350 shares to 16.87M shares, valued at $1.02B in 2018Q1, according to the filling. Dodge & Cox cut its stake in Unitedhealth Group Inc (NYSE:UNH) and reduced Union Pacific Corp (NYSE:UNP) position by 264,120 shares for a total of 13.22 million shares.

Dodge & Cox is a California-based institutional investor with more than $224.00 billion AUM in October, 2014. This fund invests only a small percentage of its assets in equities and options. Dodge & Cox is the 15th largest institutional investor in our database. Taken from Dodge & latest Adv, the fund reported to have 205 full and part-time employees. Among which 85 performing investment advisory and research functions. The institutional investor had more than 500 clients.

Eli Lilly and Company (NYSE:LLY) Ratings Coverage

In total 10 analysts cover Eli Lilly (NYSE:LLY). “Buy” rating has 4, “Sell” are 1, while 5 are “Hold”. (NYSE:LLY) has 40% bullish analysts. 17 are the (NYSE:LLY)’s ratings reports on 17 May 2018 according to StockzIntelligence Inc. On Thursday, February 1 Bank of America maintained Eli Lilly and Company (NYSE:LLY) with “Neutral” rating. On Tuesday, January 16 the rating was maintained by Jefferies with “Buy”. On Friday, March 23 the stock of Eli Lilly and Company (NYSE:LLY) earned “Buy” rating by Jefferies. The stock rating was maintained by Credit Suisse with “Hold” on Wednesday, December 13. In Wednesday, April 25 report BMO Capital Markets maintained the stock with “Market Perform” rating. On Monday, February 26 the firm earned “Buy” rating by Jefferies. On Monday, January 22 the firm has “Underperform” rating by Credit Suisse given. On Tuesday, January 16 Goldman Sachs downgraded Eli Lilly and Company (NYSE:LLY) rating. Goldman Sachs has “Hold” rating and $95.0 target. On Friday, April 13 the rating was upgraded by BMO Capital Markets to “Market Perform”. The stock rating was maintained by Leerink Swann with “Hold” on Wednesday, December 13.

Eli Lilly and Company discovers, develops, makes, and markets pharmaceutical products worldwide.The firm is valued at $82.86 billion. It operates through two divisions, Human Pharmaceutical Products and Animal Health Products.Currently it has negative earnings. The firm offers endocrinology products to treat diabetes; osteoporosis in postmenopausal women and men; human growth hormone deficiency and pediatric growth conditions; and testosterone deficiency.

Eli Lilly and Company (NYSE:LLY) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: